Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tributyrin, a butyrate precursor, impairs growth and induces apoptosis anddifferentiation in pancreatic cancer cells
Autore:
Gaschott, T; Maassen, CU; Stein, J;
Indirizzi:
Univ Frankfurt, Dept Internal Med 2, Div Gastroenterol, D-60590 Frankfurt,Germany Univ Frankfurt Frankfurt Germany D-60590 erol, D-60590 Frankfurt,Germany
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 4A, volume: 21, anno: 2001,
pagine: 2815 - 2819
SICI:
0250-7005(200107/08)21:4A<2815:TABPIG>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHAIN FATTY-ACIDS; SODIUM-BUTYRATE; LINES; COLON; PROLIFERATION; AGENT; PHARMACOKINETICS; PRODRUG; THERAPY; ANALOGS;
Keywords:
apoptosis; butyrate; Capan-l cells; differentiation; MiaPaca-2 cells; pancreas; tributyrin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Stein, J Univ Frankfurt, Dept Internal Med 2, Div Gastroenterol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany Univ Frankfurt Theodor Stern Kai 7 Frankfurt Germany D-60590 any
Citazione:
T. Gaschott et al., "Tributyrin, a butyrate precursor, impairs growth and induces apoptosis anddifferentiation in pancreatic cancer cells", ANTICANC R, 21(4A), 2001, pp. 2815-2819

Abstract

Background: The aim of this study was to investigate whether tributyrin, anatural butyrate pro-drug, as well as butyrate itself, could affect growth, differentiation and apoptosis in two human pancreatic cancer cell lines in culture. Materials and Methods: Proliferation was studied by cell counting using crystal violet staining. Cell differentiation was assessed by measuring the alkaline phosphatase activity and cell death by DAPI nuclear staining. Results: In MiaPaca-2 cells both tributyrin and butyrate reduced growth, with IC50 values of 1.1 +/- 0.2 mmol/L and 3.6 +/- 0.7 mmol/L respectively. Both 1 mmol/L tributyrin and 3 mmol/L butyrate induced a similar degreeof apoptosis in MiaPaca-2 and Capan-l cells and stimulated differentiationin Capan-l cells equally. Conclusion: Our data may provide a rationale forthe therapeutic use of peroral tributyrin in patients with pancreatic cancer, because this drug enables plasma concentrations of butyrate which inhibit growth, induce differentiation and cause apoptosis in pancreatic cancer cells.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 20:59:28